Evidence map›Paper›PMID 36609309›Full record

ArticleParasites & vectors2023

Afoxolaner (NexGard®) in pet snakes for the treatment and control of Ophionyssus natricis (Mesostigmata: Macronyssidae).

Jairo Alfonso Mendoza-Roldan, Ettore Napoli, Livia Perles, Matteo Marino, Filippo Spadola, Philippe Berny, Bernadette España, Emanuele Brianti, Frederic Beugnet, Domenico Otranto

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
5.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Jairo Alfonso Mendoza-RoldanDepartment of Veterinary Medicine, University of Bari, Valenzano, Italy.
Ettore NapoliDepartment of Veterinary Sciences, University of Messina, Messina, Italy.
Livia PerlesDepartment of Veterinary Medicine, University of Bari, Valenzano, Italy.
Matteo MarinoDepartment of Veterinary Sciences, University of Messina, Messina, Italy.
Filippo SpadolaDepartment of Veterinary Sciences, University of Messina, Messina, Italy.
Philippe BernyToxicology Lab, Vetagro Sup., 1 Av Bourgelat, 69280, Marcy L'étoile, France.
Bernadette EspañaToxicology Lab, Vetagro Sup., 1 Av Bourgelat, 69280, Marcy L'étoile, France.
Emanuele BriantiDepartment of Veterinary Sciences, University of Messina, Messina, Italy.
Frederic BeugnetBoehringer Ingelheim Animal Health, Lyon, France.
Domenico OtrantoDepartment of Veterinary Medicine, University of Bari, Valenzano, Italy. domenico.otranto@uniba.it.
University of Messina · ITUniversity of Bari Aldo Moro · ITVetAgro Sup · FRBu-Ali Sina University · IRDépartement Santé Animale · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOphionyssus natricis is the main species of mite that infests captive reptiles. High infestations may result in the host experiencing general discomfort and deleterious effects, even death. Moreover, O. natricis is an important vector of reptile vector-borne diseases and is considered to be the putative vector of the Reptarenavirus, the causal agent of the inclusion body disease. Despite the cosmopolitan distribution of O. natricis in captive reptiles, treatment options are limited. The aim of the present study was to assess the efficacy of afoxolaner (NexGard®; Boehringer Ingelheim, Ingelheim, Germany) in heavily infested, privately owned snakes, evaluate the prevalence of mites and drug availability in the plasma of treated snakes (pharmacokinetics) and perform a clinical examination of animals.

methodsThe study was conducted in two snake breeding facilities, where many snakes were infested with mites. Each animal was clinically examined and weighed, and mite infestations were assessed on the animals and in their enclosures (environment). Animals were treated with a dose of 2.5 mg afoxolaner per kilogram body weight (2.5 mg/kg) administered orally. All animals were examined pre-treatment (T0) and at various time points post-treatment (T1, 6 h; T2, 24 h; T3, 14 days; T4, 28 days). The collected mites were morphologically identified at the species level and the species identity also confirmed molecularly.

resultsOverall, 81 snakes from the two participating facilities (i.e. 70 from site 1 and 11 from site 2) were screened, and 31 (38.3%) snakes were found to have at least one mite. All mites were identified morphologically and molecularly as O. natricis. Lampropeltis was the genus of snakes with highest number of infested individuals. Mites were found to be alive on snakes at T1, but at T2 only dead mites were observed, and at T3 and T4 mites were no longer present on the animals or in their environment. No side effects were observed in the treated snakes.

conclusionsA single oral administration of afoxolaner at 2.5 mg/kg was a safe treatment for snakes and 100% effective for the eradication of natural O. natricis infestation without the need to treat the environment of the snake.

Indexed as

Dog DiseasesMite InfestationsMitesAnimalsDogsIsoxazolesNaphthalenesSnakesafoxolanerIsoxazolesNaphthalenesAfoxolanerOphionyssus natricisPharmacokineticSnakeTreatment

Identifiers

PMID36609309
PMCPMC9825044
OpenAlexW4313639047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.